All News
Is #cardiology now a specialty like #rheumatology with bDMARDs? Many pathways discussed for CVD in #rheumatoid #arthritis. And biologics for lowering lipids too! #ACR23 @ACRheum @RheumNow 14T118. More overlap of pts over time! https://t.co/blv5GmHTGe
Janet Pope ( View Tweet)
A#L06 #ACR23 @RheumNow
Refractory juv SSc 6m-2y after autolog Stem Cell Tx - 5 patients
HAQ VAS improved 75% (48-99%)
All: mRSS MCID by 6 mo, 87% aver improvement, sustained at 2y
GI: GIT mean 55% improvement, 1 unchanged
FVC stable, DLCO improv >10% in 2, 5-10% in 2
#ACRBest https://t.co/cc6YToVEO5
Eric Dein ( View Tweet)
#Cardiology imaging has advanced - work with #cardiologists to know what to order - esp for our Pts w #inflammatory #diseases #ACR23 @RheumNow @ACRheum 14T118 https://t.co/RuHJuy7Dh2
Janet Pope ( View Tweet)
Speaking of influencing in rheumatology… @RheumNow and @anisha_dua know best! #ACR23 #Facesofrheumatology https://t.co/EsppP3FPoX
Adela Castro AdelaCastro222 ( View Tweet)
MANDARA: Benralizumab v Mepolizumab in EGPA
A#L14 #ACR23 @RheumNow
P3, 52w RCT, 140 pts
Remission rate: 59% Ben, 56.5% Mep
Relapse rate 30% in both
86% Ben, 74% Mep had reduction of GC dose 50%+, 41% v 26% tapered off
SAEs: 6% Ben, 13% Mep
Concl: Non-inferiority of Ben v Mep https://t.co/mSIFsDq8eL
Eric Dein ( View Tweet)
I continue to be underwhelmed by nintedanib, esp in RA-ILD
Data from INBUILD-ON, f/u study to the INBUILD basket trial
Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD?
Need H2H vs TNFs & real DMARDs
@RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67
Mike Putman EBRheum ( View Tweet)
Real-World Issues in AxSpA: Treatment Intensification, Pregnancy
Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity.
https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv
Dr. John Cush RheumNow ( View Tweet)
MANDARA phase 3 RCT Benralizumab vs Mepolizumab in relapsing/refractory EGPA receiving SOC. Non-inferiority met. Abstr#L14 #ACR23 @RheumNow https://t.co/UnpF3RDHMa https://t.co/076SeynJx3
Richard Conway ( View Tweet)
Prelim data supports further evaluation of YTB323 in srSLE. #ACR23 Abs L13 reviews safety, CAR-T cell expansion, B cell depletion and initial efficacy in 1st 3 pts. https://t.co/aOLMhBBjgY @rheumnow https://t.co/2BoNeMe3Tg
Dr. Rachel Tate ( View Tweet)
Phase 2 RCT. Selective JAK1i LNK01001 in RA. 156 patients, 24 week (12 week PBO controlled). Abstr#L09 #ACR23 @RheumNow https://t.co/hHjL1yFH0H https://t.co/Qls4zRrRGH
Richard Conway ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
The Fallacy of Biologic Treatment to Prevent RA
It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23
https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/tc6S3fysL3
Dr. John Cush RheumNow ( View Tweet)
ICYMI - Nice blog! Choice Overload (and the Way Out) https://t.co/dBfgUadEd2 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Summary of diet effects in RA and SLE patients 👇
Dr. Sarah Patterson also shared nutrition resources for pts and clinicians
https://t.co/ae6nLrLXca
#ACR23 @Rheumnow @rheumarhyme @GerRheumDoc @doktora_ging https://t.co/8HhCHCTGLh
sheila ( View Tweet)
TM13 @ #ACR23
64 yo F w/ CHF p/w dyspnea, palpitat, chest tight
EKG: monomorph VT
- Prior EKG: intervent conduct delay, LAD
TTE: ant wall abn, EF 35-40%
LHC: LV aneurysm, nonobst CAD
cMRI: abn LV wall thickening
PET: hypermetab LV
Endomyo Bx: necrot granuloma
DX?
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Gender differences in switching biologics in PsA pts
Women had higher biologic switch rates, mainly due to lack of efficacy
Other gender specific factors include gestational reasons and different sociodemographic features
@RheumNow #ACR23 Abs#2247 https://t.co/mLm183fCBw
Robert B Chao, MD ( View Tweet)
I got a chance to interview first author Jun Chu @nihrheumatology for her study on GnRHa Reducing Premature Ovarian Insufficiency in SLE pts on CYP. Watch here @RheumNow #ACR23 https://t.co/VCvAiRs4ni
TheDaoIndex KDAO2011 ( View Tweet)
Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM
Dr. Rachel Tate ( View Tweet)
Dx: Necrotizing Sarcoid Granulomatosis (NSG)
➡️rare dz entitiy
➡️common features: cough, F, dyspnea, CP, or wt loss
➡️Bx can be necrot or non-necrot granulmoas
➡️Ddx: TB, GPA
#ACR23 @RheumNow https://t.co/zBGVriB8ka
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)